The University of Chicago Header Logo

Connection

David T. Rubin to Anti-Inflammatory Agents

Back to Details
This is a "connection" page, showing publications David T. Rubin has written about Anti-Inflammatory Agents.
David T. Rubin
Connection Strength
6.850
Anti-Inflammatory Agents
  1. Extraintestinal Manifestations of Inflammatory Bowel Disease: Current Concepts, Treatment, and Implications for Disease Management. Gastroenterology. 2021 10; 161(4):1118-1132.
    View in: PubMed
    Score: 0.639
  2. Stopping Clinical Trials in Inflammatory Bowel Disease During the COVID-19 Pandemic Is Not a Responsible Act. J Crohns Colitis. 2020 Dec 02; 14(12):1765-1768.
    View in: PubMed
    Score: 0.610
  3. ACG Clinical Guideline: Ulcerative Colitis in Adults. Am J Gastroenterol. 2019 03; 114(3):384-413.
    View in: PubMed
    Score: 0.540
  4. Higher Thioguanine Nucleotide Metabolite Levels are Associated With Better Long-term Outcomes in Patients With Inflammatory Bowel Diseases. J Clin Gastroenterol. 2018 07; 52(6):537-544.
    View in: PubMed
    Score: 0.516
  5. Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial. J Crohns Colitis. 2017 Jul 01; 11(7):785-791.
    View in: PubMed
    Score: 0.481
  6. Vedolizumab in the treatment of Crohn's disease. Expert Rev Gastroenterol Hepatol. 2016; 10(3):283-90.
    View in: PubMed
    Score: 0.436
  7. Budesonide Foam Has a Favorable Safety Profile for Inducing Remission in Mild-to-Moderate Ulcerative Proctitis or Proctosigmoiditis. Dig Dis Sci. 2015 Nov; 60(11):3408-17.
    View in: PubMed
    Score: 0.425
  8. Real-world assessment of therapy changes, suboptimal treatment and associated costs in patients with ulcerative colitis or Crohn's disease. Aliment Pharmacol Ther. 2014 May; 39(10):1143-55.
    View in: PubMed
    Score: 0.384
  9. Risk of post-operative complications associated with anti-TNF therapy in inflammatory bowel disease. World J Gastroenterol. 2012 Jan 21; 18(3):197-204.
    View in: PubMed
    Score: 0.330
  10. Effect of adalimumab on clinical laboratory parameters in patients with Crohn's disease: results from the CHARM trial. Inflamm Bowel Dis. 2012 May; 18(5):818-25.
    View in: PubMed
    Score: 0.321
  11. Predictors of adalimumab dose escalation in patients with Crohn's disease at a tertiary referral center. Inflamm Bowel Dis. 2012 Jan; 18(1):10-6.
    View in: PubMed
    Score: 0.312
  12. We once were blind and now we see: is it time to treat ulcerative colitis to achieve mucosal healing? Clin Gastroenterol Hepatol. 2011 Jun; 9(6):456-7.
    View in: PubMed
    Score: 0.312
  13. Treatment of pouchitis, Crohn's disease, cuffitis, and other inflammatory disorders of the pouch: consensus guidelines from the International Ileal Pouch Consortium. Lancet Gastroenterol Hepatol. 2022 01; 7(1):69-95.
    View in: PubMed
    Score: 0.163
  14. International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2021 12; 18(12):857-873.
    View in: PubMed
    Score: 0.161
  15. Segmental Histological Normalisation Occurs in Ulcerative Colitis but Does Not Improve Clinical Outcomes. J Crohns Colitis. 2020 Oct 05; 14(10):1345-1353.
    View in: PubMed
    Score: 0.151
  16. AGA Clinical Practice Update on Management of Inflammatory Bowel Disease During the COVID-19 Pandemic: Expert Commentary. Gastroenterology. 2020 Jul; 159(1):350-357.
    View in: PubMed
    Score: 0.146
  17. Correlation of Stool Frequency and Abdominal Pain Measures With Simple Endoscopic Score for Crohn's Disease. Inflamm Bowel Dis. 2020 01 06; 26(2):304-313.
    View in: PubMed
    Score: 0.143
  18. Exposure to Anti-tumor Necrosis Factor Medications Increases the Incidence of Pouchitis After Restorative Proctocolectomy in Patients With Ulcerative Colitis. Dis Colon Rectum. 2019 11; 62(11):1344-1351.
    View in: PubMed
    Score: 0.142
  19. Optimal doses of methotrexate combined with anti-TNF therapy to maintain clinical remission in inflammatory bowel disease. J Crohns Colitis. 2015 Apr; 9(4):312-7.
    View in: PubMed
    Score: 0.102
  20. Serum adalimumab concentration and clinical remission in patients with Crohn's disease. Inflamm Bowel Dis. 2013 May; 19(6):1112-22.
    View in: PubMed
    Score: 0.090
  21. Response to biologic therapy in Crohn's disease is improved with early treatment: an analysis of health claims data. Inflamm Bowel Dis. 2012 Dec; 18(12):2225-31.
    View in: PubMed
    Score: 0.083
  22. A practical, evidence-based guide to the use of adalimumab in Crohn's disease. Curr Med Res Opin. 2011 Sep; 27(9):1803-13.
    View in: PubMed
    Score: 0.080
  23. Clinical scenarios in IBD: optimizing the use of conventional and biologic agents. Inflamm Bowel Dis. 2010 Dec; 16 Suppl 1:S1-11.
    View in: PubMed
    Score: 0.076
  24. Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. Inflamm Bowel Dis. 2009 Sep; 15(9):1302-7.
    View in: PubMed
    Score: 0.070
  25. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial. Am J Gastroenterol. 2008 Dec; 103(12):3132-41.
    View in: PubMed
    Score: 0.066
  26. SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting. Gut. 2021 Apr; 70(4):635-640.
    View in: PubMed
    Score: 0.039
  27. Fecal Calprotectin in Assessing Endoscopic and Histological Remission in Patients with Ulcerative Colitis. Dig Dis Sci. 2018 May; 63(5):1294-1301.
    View in: PubMed
    Score: 0.031
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.